Mirtazapine Milpharm Limited,

Mirtazapine, the active ingredient in Mirtazapine Milpharm Limited, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed for major depressive disorder and related mood conditions in adult patients. GNH USA supplies Mirtazapine Milpharm Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is a tetracyclic antidepressant that modulates noradrenergic and serotonergic pathways to improve mood. - Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depression with insomnia: promotes sleep while alleviating depressive signs. - Depression with anxiety: helps lessen anxiety features that accompany depressive episodes.

Mirtazapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatotoxicity or liver enzyme elevation

Before initiating therapy, clinicians should consider several safety factors. - Monitor weight: patients often experience significant weight gain. - Assess liver function: use with caution in hepatic impairment. - Evaluate for suicidal ideation: close monitoring is needed, especially early in treatment. - Use cautiously in the elderly: higher risk of sedation and falls. - Avoid abrupt discontinuation: taper the dose under medical supervision. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Potent CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Other central nervous system depressants (alcohol, benzodiazepines): additive sedation. - Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - Warfarin: may alter anticoagulant effect, requiring INR monitoring.